Vivos Therapeutics, Inc.
VVOS
$2.10
-$0.04-1.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.08% | -18.91% | 28.17% | 18.02% | 18.46% |
| Total Depreciation and Amortization | 72.53% | 31.24% | 3.38% | -6.44% | -8.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -35.23% | 267.44% | 18.27% | 143.51% | 194.33% |
| Change in Net Operating Assets | 153.94% | -301.62% | -221.41% | -202.65% | -144.61% |
| Cash from Operations | -15.14% | -29.74% | -27.90% | -6.24% | -2.47% |
| Capital Expenditure | -71.65% | -135.85% | 24.62% | 33.41% | 36.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -975.70% | -1,104.72% | 24.62% | 33.41% | 36.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.13% | -32.32% | 92.62% | 60.31% | 146.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.45% | -113.84% | -42.95% | -26.37% | -108.84% |
| Cash from Financing | -6.05% | 25.32% | 97.71% | 63.65% | 150.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.57% | -184.46% | 93.93% | 346.11% | 192.88% |